Few Mandatory Pediatric Postmarketing Studies Completed
WEDNESDAY, Nov. 21, 2018 -- During a median follow-up of 6.8 years, only 33.8 percent of mandatory pediatric postmarketing studies were completed, according to a study published online Nov. 19 in JAMA Pediatrics.
Thomas J. Hwang, from Boston Children's Hospital, and colleagues conducted a retrospective cohort study of pediatric postmarketing studies required for 114 new drugs and new indications approved by the U.S. Food and Drug Administration from Jan. 1, 2007, to Dec. 31, 2014, and subject to Pediatric Research Equity Act requirements.
The researchers found that as of Dec. 1, 2017, 33.8 percent of pediatric studies were completed. The rates of completion were significantly lower for efficacy versus pharmacokinetic studies (28.8 versus 55.9 percent; adjusted hazard ratio, 0.31). For 33.3 percent of studies, information on randomization, blinding, comparator, end point, and study size could not be identified; of the 42 discontinued studies, no reason for discontinuation was provided for 69 percent. The results were reported for 76 percent of the completed studies. Overall, 15.8 percent of drug approvals had any pediatric efficacy, safety, or dosing information in their labels at the time of approval; after a median follow-up of 6.8 years, 41.2 percent of 114 drug labels had any pediatric information.
"To reduce off-label and unsafe prescribing of medicines to children, mandatory pediatric research must be completed in a timely fashion and the results made widely available to clinicians and patients," the authors write.
One author disclosed previous employment by Blackstone and Bain Capital, which have invested in health care companies.
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.